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PERSPECTIVE

OPEN

Limitations in predicting radiation-induced pharmaceutical
instability during long-duration spaceﬂight
Rebecca S. Blue

1,2

, Jeffery C. Chancellor

3

, Erik L. Antonsen4,5, Tina M. Bayuse6, Vernie R. Daniels6 and Virginia E. Wotring7

As human spaceﬂight seeks to expand beyond low-Earth orbit, NASA and its international partners face numerous challenges
related to ensuring the safety of their astronauts, including the need to provide a safe and effective pharmacy for long-duration
spaceﬂight. Historical missions have relied upon frequent resupply of onboard pharmaceuticals; as a result, there has been little
study into the effects of long-term exposure of pharmaceuticals to the space environment. Of particular concern are the long-term
effects of space radiation on drug stability, especially as missions venture away from the protective proximity of the Earth. Here we
highlight the risk of space radiation to pharmaceuticals during exploration spaceﬂight, identifying the limitations of current
understanding. We further seek to identify ways in which these limitations could be addressed through dedicated research efforts
aimed toward the rapid development of an effective pharmacy for future spaceﬂight endeavors.
npj Microgravity (2019)5:15 ; https://doi.org/10.1038/s41526-019-0076-1

INTRODUCTION
With the expansion of human spaceﬂight outside of low-Earth
orbit (LEO), NASA and its international partners face numerous
challenges related to ensuring the safety of their astronauts.
Among these challenges is the ability to provide a safe and
effective pharmacy with sufﬁcient capability to manage both
planned and unforeseen medical conditions that may arise during
ﬂight. The ability to provide a safe and effective pharmacy to
crews is contingent upon multiple factors, such as the stability of
any medication for the duration of a given mission, the
effectiveness of that medication in the unique space environment,
and the provision of appropriate and sufﬁcient medications to
meet the unique physiological and psychological challenges the
crew may face.
There is a paucity of evidence regarding pharmaceutical
stability in the space environment, largely because this issue has
not historically been a pressing concern for human spaceﬂight.
Short-duration ﬂights of the Mercury, Gemini, Apollo, and Space
Shuttle eras minimized the need for prolonged medication shelf
life, and the selection of healthy crew members minimized the
need for ongoing medication provision for chronic disease. Careful
maintenance of crew health and stringent ﬂight rules regarding
the more dangerous activities during spaceﬂight, such as
extravehicular activity, have largely obviated the need for
emergency medication provision. Even now, with missions to
the International Space Station (ISS) lasting 6 months or longer,
crews have been able to rely on medication availability through
retirement of expired medications and frequent resupply rather
than contending with questions of degradation, storage, and the
impact of the space environment (with environmental concerns
related to a myriad of factors such as vibration, humidity, and
space radiation exposure). As a result, investments in the

systematic collection of data for the characterization of medication use, efﬁcacy, side effects, pharmacokinetics, pharmacodynamics, and long-term stability have been a lower priority than
other health and human performance investments. With the push
for exploration missions to the moon and Mars, these questions
have become a more pressing concern.
One potential risk to pharmaceutical stability arises from longterm exposure to the space radiation environment. While gamma
radiation exposure has been used terrestrially for sterilization
procedures in select pharmaceuticals, space radiation differs
considerably from such practices because of differences in the
type of radiation, dose, dose-rate, and length of exposure. It is
unclear whether long-term exposure to space radiation may affect
stability, alter drug ingredients, or produce potentially toxic
byproducts, particularly in drugs that have undergone degradation reactions.
Here we seek to present the current understanding of
pharmaceutical stability in the space radiation environment. In
particular, we have attempted to highlight the gaps in current
knowledge and the difﬁculties in translating terrestrial-based
radiation studies to a meaningful interpretation of drug response
to space radiation. We hope to identify high-yield opportunities
for future research that might better deﬁne and mitigate the
space radiation risk to a future formulary for exploration
spaceﬂight.
THE INTERPLANETARY SPACE RADIATION ENVIRONMENT
The effects of radiation are due to the transfer of energy from a
charged particle to the medium it travels through. The amount of
energy that can be transferred is a function of the particle’s kinetic
energy, charge, and mass.1,2 The effects of indirect ionizing

1
Aerospace Medicine and Vestibular Research Laboratory, The Mayo Clinic Arizona, Scottsdale, AZ 85054, USA; 2GeoControl Systems, Inc, Houston, TX 77058, USA; 3Department of
Physics & Astronomy, Texas A&M University, College Station, TX 77843, USA; 4Department of Emergency Medicine and Center for Space Medicine, Baylor College of Medicine,
Houston, TX 77030, USA; 5National Aeronautics and Space Administration (NASA), Johnson Space Center, Houston, TX 77058, USA; 6KBR, Houston, TX 77058, USA and
7
Department of Pharmacology and Chemical Biology and Center for Space Medicine, Baylor College of Medicine, Houston, TX 77030, USA
Correspondence: Rebecca S. Blue (rblue.md@gmail.com)

Received: 7 September 2018 Accepted: 7 May 2019

Published in cooperation with the Biodesign Institute at Arizona State University, with the support of NASA

R.S. Blue et al.

1234567890():,;

2
radiation (e.g., gamma and x-ray) are negliglible compared to the
effects caused by direct ionizing charged-particle risk. The more
charge a particle has, the greater ability it has to ionize the
medium it traverses, depositing more energy per unit path length
[deﬁned as increased linear energy transfer (LET)] in a traversed
material.
Future space exploration endeavors will include human
expeditions beyond the protection of the Earth’s magnetic ﬁeld.
These long-duration missions, which may span months to years,
will require additional protection for the human crews onboard.
The space radiation environment is a complex mix of charged
particles originating from several sources. Within an exploration
vehicle (one intended to travel outside of the Earth’s geomagnetic
ﬁeld), the intravehicular radiation environment primarily consists
of relativistic heavy-charged particles attributed to galactic cosmic
rays (GCR) (chronic, isotropic background radiation). The GCR
spectrum, and thus the intravehicular radiation environment,
primarily consists of ionized hydrogen (protons, ~85%) and helium
(alpha, ~14%) nuclei, but also includes less-abundant ionized
particles of higher atomic weight.3,4 Despite their rarity, heavier
particles contribute a disproportionately high amount of overall
radiation dose exposure due to their relatively high LET. In
addition, as GCR ions pass through vehicular structures, interaction with vehicle materials can cause fragmentation (or “spallation”) of heavier ions into more numerous particles of lower
atomic weight. This process can produce cascades of ions,
resulting in a destructive capability in addition to that of the
primary ions. Accounting for all such interactions increases the
complexity of predicting the intravehicular radiation environment.
It is particularly difﬁcult to shield from GCR exposures given the
isotropic, highly penetrating nature and the relative energies of
the GCR spectra.5
An additional, off-nominal source of charged particle radiation
can be attributed to solar particle events (SPEs), where particles
are ejected from the sun in prompt and short-lived bursts of
energy. SPEs consist primarily of protons and electrons with a
relatively small contribution from heavy nuclei. Unlike GCR, SPEs
are anisotropic.6 SPE radiation is primarily composed of protons
with kinetic energies ranging from 10 MeV to several GeV
(determined by the relativistic speed of particles).3 SPEs are
capable of accelerating an abundance of protons that can
occasionally result in high dose-rates in the interplanetary
environment. For example, a particularly large event in October
1989 is predicted to have delivered dose-rates as high as
1,454 mGy/h for a short period of time to an exposed astronaut
in a vehicle with 5 g/cm2 of aluminum-equivalent shielding
traveling in interplanetary space.3,7 While rare, SPE exposure
would be in addition to the nominal intravehicular dose,
attributed to GCR nuclei, expected to be approximately
0.028 mGy/h during travel in interplanetary space.4 Interplanetary
intravehicular doses would be altered by the peak ﬂux, energy
spectrum, and duration of any given SPE, as well as shielding
thickness and material makeup of the vehicle. Similarly, the
contribution of radiation exposure from SPEs and resultant effects
on pharmaceuticals would depend upon intravehicular dose and
any additional shielding.
As missions to the moon or Mars will expand human presence
from LEO to interplanetary space, intravehicular radiation exposure will increase. Vehicles, and the pharmaceuticals onboard, will
be exposed to higher cumulative GCR exposure and increased risk
for transient SPE exposures. As a result, the risk of radiationinduced alterations of pharmaceutical stability, structure, potency,
and potential toxicity will increase with future missions (Fig. 1).
MECHANISMS OF RADIATION IMPACT
A majority of pharmaceutical radiation risk research is derived
from terrestrial analogs rather than the full particle and energy
npj Microgravity (2019) 15

spectrum of the space radiation environment. Accordingly,
differences in the relative abilities of terrestrial and space radiation
to induce damage in a target have yet to be elucidated. This
property of different types of radiation to induce different levels
and kinds of damage is known as radiation quality. Radiation
quality is thought to be dependent on LET, which can be
characterized by the energy deposition pattern. Charged particles
traverse a material in an approximately straight line, transferring
energy through interactions with the medium’s nuclei and
electrons. The imparted energy may be enough to knock an
electron out of an atom, ionizing the atom or leaving it in an
excited, nonionized state. The ejected electron can have enough
energy to leave the immediate vicinity of the charged particle’s
path and produce a notable track of its own. This results in a
densely ionizing core along the charged particle’s path (where
energy continues to be deposited in an approximately straight
line), as well as a sparsely ionizing penumbra generated by
expelled electrons (where energy is deposited throughout the
material randomly).
In addition to differences in radiation quality, substrate
composition is an important factor in radiation-induced damage.
To date, most radiation research has been conducted in biological
models, where a majority of the substrate is water. In this scenario,
radiation is more likely to hit water than a biologically relevant
target (e.g., DNA). However, even if radiation impacts water rather
than a target, it can still induce damage to a target via generation
of free radicals, which can diffuse to interact and ionize a target
within range. This form of damage is known as indirect ionization,
while damage caused from radiation hitting a target is known as
direct ionization. In pharmaceuticals, where a greater percentage
of substrate composition consists of target molecules, direct
ionization is far more likely than in biological substrates. The
difference between the percentage of target interactions that are
direct versus indirect is highly dependent on substrate and
projectile energy.
It has been observed that direct ionization can cause increased
damage compared to indirect ionization, particularly in the
decomposition of chemical bonds, creation of radiolysis products,
and damage to polymer structure.8–10 Studies using biological
substrates therefore do not provide good analogs for pharmaceutical research. Furthermore, clustered damage imparted by
densely ionizing space radiation combined with the higher target
concentration in pharmaceutical formularies could potentially
interact, resulting in outcomes that have not yet been
characterized.
CHALLENGES IN REPRODUCING RADIATION DOSE, DOSE-RATE,
AND FORMULATION SENSITIVITY
Another area of uncertainty is the effect of low doses on
pharmaceuticals. Terrestrial pharmaceutical radiosterilization techniques generally use doses of 25–50 kGy, which far exceed those
expected for even cumulative Mars mission doses (~0.5 Gy).
Delivery of radiosterilization doses over a matter of minutes or
hours considerably exceeds the dose-rates anticipated in interplanetary space, where such doses would be accrued over 2–3
years by current estimates.
It has been suggested that if a pharmaceutical is found to be
stable at higher doses or dose-rates (such as those provided by
radiosterilization techniques), then the pharmaceutical should be
stable at more limited exposures (such as those delivered in
space).11 Some evidence for this argument has been provided by
the expected level of damage from indirect ionization. Despite the
relatively higher concentration of target molecules in pharmaceutical than in biological substrates, damage to pharmaceuticals
from indirect ionization does still occur, particularly in liquid
pharmaceuticals where target molecules are less concentrated
than in solid formulations. Indirect ionization-induced damage
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Fig. 1 Factors limiting understanding of pharmaceutical stability in the space radiation environment. Radiation from galactic cosmic rays
(GCR) is not graphically depicted but should be considered ubiquitous in the space environment. PK/PD: pharmacokinetics/
pharmacodynamics

stems from the formation of free radical species; in water-based
formulations, this includes the generation of radical oxygen
species (oxygen ions and hydrogen peroxide, H2O2) from the
breakdown of water.12–14 Studies have indicated that the
concentration of these radicals from exposures to radiosterilization doses (25–50 kGy) is generally well below toxic levels.15,16 A
recent NASA technical paper indicated that nanomolar concentrations of radiation byproducts could be produced in exposed
pharmaceuticals, but cited low anticipated radiolytic yield in
liquid-based pharmaceuticals (based on modeled calculations) as
sufﬁcient evidence that irradiated pharmaceuticals should be
stable in the space environment.11
However, even the low nanomolar concentrations of ions
predicted by that technical report could be enough to sufﬁciently
alter local pH in drug products, which could alter chemistry or
drive degradation reactions.17 In addition, studies using electron
spin resonance, a sensitive method for the detection of free
radicals,18,19 have demonstrated that alteration of radiation dose
changes the concentration and type of free radicals produced,
often with unpredicted complexity or type of resultant radical
species.19 These complex reactions could alter subsequent radicalinduced damage.19 Dose-rate may be an important factor in the
activity of radical species, and many pharmaceuticals are
demonstrated to be more stable at higher dose-rates. It has been
theorized that high dose-rate increases oxygen consumption,
resulting in decreased presence of oxygen radicals (or the rapid
consumption of any radical species generated) and associated
damage.16,19 Shorter duration exposures may produce fewer long-

lived oxygen radical species and, as a result, less prolonged
opportunity for delayed damage than protracted exposures. In
evidence to these arguments, one historical study of spaceﬂightapproved pharmaceuticals compared drug stability at variable
radiation dose ranging from 0.1 to 50 Gy and found drug
degradation associated with moderate radiation exposure where
no instability was noted at higher doses.20 It is worth reiterating
that these dose ranges include exposures that are substantially
greater than even cumulative anticipated doses in long-duration,
exploration spaceﬂight.
Liquid pharmaceuticals are often considered less stable than
solid or powdered drugs, given the greater potential for free
radical formation in water-based formulations, the possibility of
interactions between substrate and excipients (the pharmacologically inert compounds in a given dosage formulation), incomplete
dissolution of substrate, crystallization of dissolved compounds,
and other alterations of drug suspensions over time. Water-based
drugs will undergo more frequent hydrolysis reactions, driving
more prevalent and more rapid degradation reactions. As a result,
the rare discussions of pharmaceutical stability in the context of
space radiation have focused on liquid formulations and
postulated that, should liquid formulations be determined to be
stable in the space radiation environment, solid or semisolid
formulations would be of no additional concern.11 However, some
studies demonstrate radiation-induced instability in solid or
powder formulations, with reports of radical trapping in excipient
lattices leading to a longer presence of free radicals in powder or
solid drugs than in liquid formulations.21–24 In addition, the
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interaction of particles with solid or powder substrates may
produce increased types and complexity of ion species due to
spallation. Spallation ions impacting stored pharmaceuticals may
cause increased direct and indirect ionizations or induce
additional chemical reactivity in the substrate. In short, it is
unclear how drugs of any formulation may respond to the unique
qualities of space radiation, simply because such responses have
not been studied to any degree of ﬁdelity.
Given the uncertainty of drug response to alterations of dose,
dose-rate, or exposure time, radiosterilization is only approved for
well-documented procedures of declared dosage (most commonly 25–50 kGy) and dose-rate, and deviation from the
designated dose or dose-rate is assumed to be capable of altering
the ﬁnal drug product.16,19 In evidence to this concern, the United
States Pharmacopeia (USP) regards radiosterilized pharmaceuticals as entirely new products, and pharmaceutical companies are
required to submit new drug applications and demonstrate safety,
potency, and lack of toxic breakdown products for approval of
radiosterilization in any marketed drug.16,25 The use of terrestrial
analog radiation to predict the response of pharmaceuticals in the
space environment directly contradicts the standard approach to
safety and stability review of irradiated pharmaceuticals. Finally, it
should be noted that many of the pharmaceuticals currently
included in a spaceﬂight formulary are not approved by the U.S.
Food and Drug Administration (FDA) for terrestrial radiosterilization procedures (Table 1).
CHALLENGES IN SIMULATING THE SPACE ENVIRONMENT
Accurate simulation of the complex space radiation environment
for pharmaceutical testing via terrestrial analog is currently not
possible, given the limitations in radiation type and dose-rate of
exposure. Space radiation studies, pharmaceutical or otherwise,
often make use of a recently updated GCR simulator at the NASA
Space Radiation Laboratory (NSRL) at Brookhaven National
Laboratory in Brookhaven, New York. To date, the NSRL is the
only US government facility capable of generating heavy-charged
particles at energies and spectra that approximate the space
environment.26,27 Recent improvements now allow for rapid
switching between ion species, providing rapid and consecutive
exposures to different mono-energetic ion beams.26 Rapid
switching of ion beams may be sufﬁcient in simulation of the
complex space environment, particularly as previous modeling
has suggested that the likelihood of multiple ion species
traversing a small volume at the same time (i.e., traversing a
single-drug tablet) is exceedingly low.28 This rapid switching
technique is a potential improvement when compared to the use
of photon or single-ion exposures, and offers more insight than
studies with considerably higher doses than those expected
during spaceﬂight, such as the doses used in radiosterilization
literature.3,26
However, even this simulator utilizes exposures that are
appreciably different from those anticipated in the interplanetary
space environment, generally delivering cumulative anticipated
mission doses over short periods of time.26 While the NSRL
simulator is capable of providing more protracted doses,
limitations of funding for long-term experiments generally limit
exposure times, causing deviation of the analog from GCR. The
simulator cannot generate the full spectrum of ions or spallation
ions that make up the GCR spectrum; instead, exposures are
limited to only a sampling of some of the heavy ions that
contribute to GCR, and these ions are delivered sequentially rather
than simultaneously. Further, the simulator lacks the capacity to
generate the pions (subatomic particles) or neutrons that would
follow spallation reactions in the intravehicular environment,3,27
though these would be expected to account for 15–20% of an
intravehicular exposure.27,29 These factors may limit the ability to
npj Microgravity (2019) 15

translate terrestrial analog studies to an understanding of the true
risk of space radiation pharmaceutical exposure.
Even so, the NSRL simulator is one of the few simulators
available to study space-like radiation in the terrestrial environment. To date, there are remarkably few studies of pharmaceuticals at this facility. In 2011, Chuong et al. studied the stability of
solid formulations of vitamin B during spaceﬂight and in terrestrial
radiation analogs, making use of an older radiation simulator at
the NSRL for some exposures.30 The authors studied vitamins that
had ﬂown onboard the Space Shuttle and ISS for 2–4 weeks or
12–19 months, comparing them to terrestrial controls and
vitamins exposed to the terrestrial radiation beam. While the
NSRL exposures were used as a terrestrial radiation study arm to
examine radiation effects on the vitamin, it is noteworthy that the
NSRL exposures were monoenergetic exposures of 0.1–50 Gy,
using either hydrogen or iron radiation sources.30 The upper limits
of exposures in this study greatly exceed those expected during
even long duration and exploration spaceﬂight.
The USP allows variation of the active pharmaceutical ingredient
(API, the ingredient imparting the desired physiological effect of a
medication) within 90–150% of package label content for vitamin
B. The Chuong study did identify statistically signiﬁcant, though
acceptable, variation in content of ground (unﬂown, nonirradiated) and NSRL-irradiated samples, and even identiﬁed one
ﬂown sample with API concentration well below acceptable
ranges.30 However, the authors suggest that instability was most
likely related to API formulation, excipient interaction, or even
packaging, and stated that, since NSRL samples were found to be
stable (at notably higher dose-rate than ﬂown samples), radiation
was not the cause of instability.30 As discussed above, this
reasoning is questionable, given the numerous factors that limit
translation of simulated radiation exposures to the true space
environment.
Additional research conducted at the NSRL by NASA on
numerous pharmaceuticals in an effort to delineate the effects
of various radiation doses on drug stability similarly utilized
0.1–50 Gy doses of proton or iron monoenergetic beams.20 Data
released suggest dose-variable alterations of API, with increased
degradation noted at 10 Gy exposures compared with those at
50 Gy exposures delivered over equivalent time intervals (Fig. 2).20
Study exposures are still notably higher than those expected
during spaceﬂight but suggest that stability at high-dose
exposures may not necessarily translate to stability at low-dose
exposures, and that dose and dose-rate alterations may signiﬁcantly impact the stability. Unfortunately, there is only limited
documentation regarding research design or even the full results
of this study, limiting our ability to fully interpret the ﬁndings.
MECHANISMS OF PHARMACEUTICAL INSTABILITY
Pharmaceuticals can become unstable through alteration of either
their physical or their chemical properties. Alteration of physical
properties includes changes in appearance or consistency;
alteration of chemical properties includes loss of potency,
alteration of excipients, excipient-active ingredient interactions,
or toxic degradation.31,32 In order to determine that a pharmaceutical is unchanged by exposure to the radiation environment, a
drug must be demonstrated following exposure to having no
signiﬁcant alteration of its API(s) while at the same time have no
signiﬁcant development of degradation products that are either
toxic themselves or in some way alter the pharmaceutical
properties of the original medication.17 The USP provides guidelines for acceptable API content in medications approved by the
FDA, commonly within 10% of label-speciﬁed content (though this
can vary considerably by drug type or API).25 A medication would
be considered radiosensitive if API concentration fails to meet USP
requirements following radiation exposure. Alterations of API can
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Table 1.

Factors affecting the translation of terrestrial pharmaceutical stability to the space environment

Factor

Translational limitation

Mechanisms of damage: direct versus indirect Primary damage from impact of heavy ions on substrate, and differential generation of free radicals
ionization
Dose delivery

Dose and dose-rate impacts formation of free radicals, catalysis of chemical reactions, and energy
transfer

Radiation type

Different response to gamma, x-ray, electron beam, proton, heavy ion, and mixed ion exposures

Intravehicular environment simulation

Intravehicular radiation spectra markedly different depending on hull or shielding material

Limited translational space research

Few studies, each with numerous confounders, poor ground controls, poor sample size, and delayed
or limited processing

Formulation sensitivity

Formulations of very similar drugs can have signiﬁcant variation of response to radiation exposure;
alterations in radiation response of liquid, solid, or powder formulations

Spaceﬂight confounders

Shelf-life concerns, pharmaceutical age, repackaging and materials interactions, and alterations of
pharmacokinetics/pharmacodynamics in ﬂight

Limited research plans

Rapid progression to exploration spaceﬂight (with lunar and Mars missions in planning stages), and
poor understanding of risk proﬁle for informed decision-making

Fe

H+

Fe

H+

Fig. 2 NASA data from an NSRL study performed by Daniel et al. demonstrating variable drug sensitivity to radiation exposure for clavulanate
(as a combination medication, amoxicillin-clavulanate) and promethazine.20 All drug products were measured at time zero; control and
irradiated products were analyzed at the same time following exposures. The solid green line indicates USP-accepted lower limits of percent
API content compared to label claims. Note the variable sensitivity both by radiation beam exposure (proton, in red, or iron, in blue) and by
dose received (0.1–50 Gy). In this study, drugs demonstrated increased degradation to 10 Gy exposures compared to 50 Gy exposures,
suggesting that pharmaceutical stability at higher dose exposure may not necessarily translate to stability at lower dose exposures. However,
the dose and dose-rate of high exposures were signiﬁcantly greater than even cumulative anticipated doses in long-duration, exploration
spaceﬂight. Further, there is only limited documentation regarding research design or even the full results of this study, limiting our ability to
interpret the ﬁndings

affect drug potency, efﬁcacy, and safety, rendering the drug less
effective, ineffective, or potentially dangerous.
There are numerous documented cases of pharmaceuticals
being altered by radiation exposure at sterilization doses
(25–50 kGy). For example, irradiation of metoclopramide hydrochloride produced a number of degradation products following
radiation exposure,33 and gamma sterilization of certain beta
blockers has been demonstrated to alter the pharmaceuticals’
color and appearance and affect the melting point of the drug
preparations.34 Even compounds that are molecularly similar may
have vastly different responses to irradiation.35 Cephradine and
cefotaxime, both solid-form cephalosporin antibiotics of similar
molecular structure, demonstrate signiﬁcantly different radiosensitivity when exposed to identical sterilization doses of gamma
radiation. Cephradine degrades signiﬁcantly and has been
determined to be unstable under irradiation36 whereas cefotaxime
demonstrates high resistance and stability.37,38 As molecular
alterations can change the saturation of the compound or the
presence or absence of reactive groups, such as alcohols, acids, or

ketones, even minor differences in API structure can affect
radiosensitivity.
In addition to altering API, radiation exposure can result in the
generation of degradation products and may alter the medication,
whether or not the API is affected, by damaging the structure or
action of excipients. For example, radiation is known to alter the
chemical structure of various polymer drug delivery systems,
causing increased cross-linking of polymers in some cases and
inducing polymer chain breakage in others.35,39 Cross-linked
polymers, with higher molecular weight, may cause issues with
insolubility,40 and chain breakage of some polymeric microspheres used for drug delivery have been associated with high
production of free radicals and instability of the resultant
compounds.35,41 In some studies, alteration of excipients has
been demonstrated to affect dissolution rates and controlled
release of API.42,43
Radiosensitivity is highly speciﬁc to dose, dose-rate, radiation
type (photon, electron, proton, heavy ion, etc.), chemical
composition, excipient content, and drug formulation. However,
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drug age, repackaging, shelf life, and radiation exposure will
interact to determine pharmaceutical response.
There have been very few examinations of pharmaceuticals
actually exposed to the space environment, including a groundcontrolled study of API in ﬂown pharmaceuticals conducted by Du
et al.,48 and a convenience sampling of pharmaceuticals returned
to the Earth after > 550 days aboard the ISS by Wotring (see
Fig. 3).49 More recently, Cory et al.50 and Wu et al.51 sought to
analyze the potency, purity, and drug degradation in certain
pharmaceuticals ﬂown aboard the ISS, though these results have
yet to be published. Two additional papers addressed multivitamin stability after spaceﬂight exposure, including Chuong
et al.30 and Zwart et al.52 In general, most pharmaceuticals tested
after ﬂight have been found to meet USP requirements for API
concentration, though notable exceptions occurred. For example,
Du et al. found that amoxicillin-clavulanate, levoﬂoxacin, trimethoprim, sulfamethoxazole, furosemide, and levothyroxine degraded
before their expiration dates.17,48 The study additionally identiﬁed
alterations of physical appearance of some medications. Wotring
identiﬁed degradation and impurity products in aspirin, ibuprofen,
loratadine, modaﬁnil, and zolpidem.49 The two multivitamin
studies identiﬁed alteration of multivitamins over time in both
ground and ﬂown samples when compared to time-zero controls,
but neither found convincing evidence of degradation speciﬁc to
spaceﬂight-ﬂown formulations.30,52 While these studies have
provided at least some much-needed pilot data, they are limited
by the ability to provide adequate ground control, control of

it must also be stated that any radiation-induced pharmaceutical
risk must be weighed in the context of the multitude of other
factors that may render a ﬂown drug unstable in the space
environment. Mission duration will soon extend beyond approved
shelf life for many medications currently included in onboard
medical kits. Current medications aboard the ISS are replenished
through regular resupply and removal of older drugs; this may not
be possible with future missions to the moon or Mars.17 Older
drugs may be at higher risk of degradation from chronic exposure
to the radiation environment.
NASA currently repackages some of the ﬂown pharmaceuticals
to manage mass and volume constraints and to limit packaging
waste in the closed environment of a space vehicle. However,
repackaging itself may affect the shelf life or stability of stored
medications, or alter their response to radiation exposure.17,44 For
example, nuclei interacting with packaging material could
produce additional progeny ions that alter the chemical
composition of pharmaceuticals within.31 Previous studies have
suggested various packaging materials that may be intrinsically
better for radiation shielding, such as polyethylene;31,45–47
however, there are insufﬁcient data regarding the ideal packaging
technique or long-term shelf life of pharmaceuticals packaged in
such materials, and any novel packaging approach intended for
use onboard future missions would be subject to USP review and
guidelines.25 Ultimately, choice of packaging materials should
address radiation sensitivity as well as additional shelf-life
concerns, particularly as it remains unclear how the factors of
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API (B Vitamin only)
Centrum Silver® Multivitamin •
Vitamin D Supplement •

Centrum Silver® Multivitamin*
Women’s Once-A-Day® Multivitamin*

API,
Degradants

Aspirin
Acetaminophen**
Ibuprofen
Loratadine** †
Loperamide †
Pseudoephedrine
Melatonin

Phenytoin
Sertraline
Valacyclovir
Ibuprofen
Promethazine
Azithromycin

Zolpidem †

Fig. 3 To date, there have been few studies of pharmaceuticals ﬂown in the space environment. The studies presented in the ﬁgure included
various evaluations of active pharmaceutical ingredient (API), physical characteristics, impurity products, and degradation, as indicated.30,48–52
Only one study by Chuong et al.30 included “radiation arm,” a subset of ground controls that were irradiated with either hydrogen or iron ions
at high dose and dose-rate dissimilar to the space environment. Drugs in red text were found to have alterations of API, physical
characteristics, or contain signiﬁcant concentrations of degradants or impurities after ﬂight in one or more preparation of the indicated
pharmaceutical. *Multivitamin preparations were analyzed only for B-complex API stability. **Drugs contained API concentrations within
acceptable limits at the time of study analysis, but would fail API analysis according to current standards. Drugs contained unspeciﬁed or
unidentiﬁed impurity products of unknown signiﬁcance. • Multivitamin content demonstrated time-related instability but showed no
alteration speciﬁcally related to spaceﬂight exposure
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confounders, or appropriate reproducibility, given the limited
sample size, and can provide only an initial awareness that ﬂown
pharmaceuticals may not be stable in the space environment. It is
worth emphasizing that pilot data do suggest that expected
radiation exposures may be sufﬁcient to affect medication
stability. While yet unpublished, reported results from more
recent experiments performed by Cory et al. and Wu et al. were
similarly limited by exposure-time variables, limited ground
controls, and drug lot variability, but again suggest instability
despite theoretical expectations to the contrary.50,51
Finally, despite decades of pharmaceutical use in spaceﬂight,
there is limited knowledge regarding alterations of pharmacokinetics (absorption, metabolism, and excretion of a medication)
and pharmacodynamics (drug effects on the body) in the space
environment. As the human body undergoes signiﬁcant physiological and metabolic changes during spaceﬂight, it stands to
reason that the effects of pharmaceuticals on an astronaut may
change during ﬂight.53 However, research on this issue has largely
been limited to observational reports and analog studies.17,53
Without directed studies to examine the multifactorial impact of
the space environment on pharmaceutical response, it is difﬁcult
to fully understand how the additional risks from space radiation
may further alter drug response, if at all, during exploration
missions.
DISCUSSION
Numerous confounders, limited spaceﬂight studies, and challenges in translation of terrestrial analog evidence to spaceﬂight
have all hindered our ability to draw meaningful conclusions
regarding the stability of pharmaceuticals during exploration
spaceﬂight. As NASA looks toward the challenges associated with
missions involving increased distance from the Earth, the current
inability to provide a safe and effective pharmacy for exploration
spaceﬂight has been identiﬁed as a major research gap.54 To
address this issue, NASA recently developed a Pharmacy Research
Plan in which pharmaceutical stability and radiation risk are
highlighted as unknowns that should be addressed in dedicated
research efforts prior to lunar or Mars missions.55 However, this
research plan faces challenges including approaching mission
design-freeze deadlines and a need to declare a planned
formulary for fast-approaching exploration missions, expected to
occur within the next decade of spaceﬂight.
As an adjunct to NASA’s research plan, recent literature has
provided potential solutions for storage- and radiation-related
stability concerns. For example, there has been some suggestion
that cryogenic storage conditions may be protective to pharmaceuticals during spaceﬂight.31,56 Such methods have been
demonstrated to be successful during radiosterilization processes,
providing increased stability of medications during gamma or xray exposure.31,57,58 Even so, some formulations may demonstrate
decreased stability with freezing; for many drugs, the effects are
unknown or unstudied. There have been no studies of cryogenically stored pharmaceuticals exposed to space-like radiation
doses, dose-rates, or spectral complexity. It is difﬁcult to predict
the response of cryogenic pharmaceuticals to the space environment, given the multitude of confounding factors and the paucity
of data available.
Similarly, previous literature has discussed the potential
inclusion of “space-hardy” formulations, such as use of excipients
believed to be more stable in a radiation environment.31,49 For
example, formulations including starch, stearate, cellulose, and
dextrose may be more likely to be stable than alternatives, based
on results from the 2016 Wotring study.31,49 Other options include
preparations including excipients such as mannitol, nicotinamide,
and pyridoxine, which have demonstrated radioprotective properties in terrestrial sterilization processing.31 A more thorough
discussion of potential excipients for improved stability,

radioprotective qualities, and antioxidant effects can be found in
Mehta et al.31 However, it should be reiterated that much of the
literature supporting inclusion or exclusion of excipients for
protective or stability properties is again based on incomplete
data, convenience sampling, or radiation exposures dissimilar to
the space environment, limiting the translation of ﬁndings,
particularly, for long-duration, exploration missions. Furthermore,
altering or adding excipients would change drug formulation; the
resultant product would be considered a new drug and, as per
USP regulations, would require a new application for drug
approval and demonstration of safety, potency, and lack of toxic
breakdown products.
Finally, there has been a discussion of limiting the impact of
pharmaceutical irradiation through the inclusion of onboard
shielding.56 In collaborative efforts to protect human crew from
radiation exposure, there has been much discussion regarding the
inclusion of a heavily shielded compartment of thick aluminum or
other radioprotective material, or alternatively by the use of
“multipurpose shielding solutions,” such as barriers composed of
water or food supplies, on exploration vehicles.56,59,60 Pharmaceuticals could be stored within a shielded compartment to
reduce radiation exposures. While these innovative efforts show
promise, it is important to remember that shielding designs may
be limited by mass and volume constraints and lift-mass
capabilities of the launching vehicle. It is premature to assume
that idealized shielding will be successfully implemented in early
exploration vehicles. Many of the shield designs are intended for
“just-in-time” deployment for protection of crew;60 in such
circumstances, crew would have to retrieve onboard pharmacy
stores and transfer them into the shielded space to protect drugs
from SPEs. Even if a high degree of shielding were to be
implemented, such a compartment would only mitigate transient
exposures associated with large SPEs, and protracted exposure to
GCR would continue to pose a threat to drug stability in longduration spaceﬂight.
Ultimately, successful mitigation of radiation risk relies upon a
more thorough understanding of the potential effects of radiation
upon pharmaceuticals, insight regarding which pharmaceuticals
are at highest risk for radiation-induced damage, and an
awareness of how the myriad of spaceﬂight-related factors (e.g.,
altered pharmacokinetics and pharmacodynamics, radiation dose,
radiation dose-rate, packaging, shelf life, etc.) affect an exposed
drug. Careful and controlled study of pharmaceutical stability, with
ground controls and appropriate sample size, would greatly
improve our understanding of the multifactorial risks to pharmaceuticals in space. Additional ground-based studies comparing the
effects of gamma, x-ray, or electron beam to proton or heavy ion
exposure may improve understanding of how to better translate
terrestrial literature to the context of space radiation. Utilization of
the ISS as a research platform, with long-duration storage of
pharmaceuticals and well-designed and controlled studies of shelf
life and radiation exposure, could provide much-needed understanding of stability in actual spaceﬂight conditions. However,
such studies would need to be initiated rapidly, as the ISS is
intended for decommissioning within the next decade. With
rapidly approaching exploration mission dates, NASA and its
international partners seek a mature pharmaceutical formulary
that can be realized before vehicle and mission design freezes
occur. Inclusion of pharmaceuticals (particularly, novel or complex
pharmaceuticals not currently included in the ISS formulary)
onboard future manned or unmanned missions outside of LEO
could provide additional data of drug stability in the actual deepspace environment; however, most of these missions do not
return payloads to the Earth, limiting analysis options. Maximizing
analysis opportunities requires programmatic commitments to
sample return; this in turn depends upon an increased understanding of the importance of these data.
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As a comprehensive research plan onboard the ISS may not be
feasible, given time and ﬁnancial constraints, a study of the
comparative effects of single- and multienergetic exposures may
improve our understanding of the complexity of the space
radiation environment and its impact on pharmaceuticals. As
discussed above, use of dose and dose-rates that more closely
simulate the space environment may provide more useful or
accurate results than reliance upon high-dose and dose-rate
exposures. Further, inclusion of shielding materials in terrestrial
analog design, to both mitigate dose and simulate potential
spallation reactions, may better mimic the ionic composition of
the intravehicular environment.29 Comparative studies of drugs,
both including and excluding shielding or packaging materials,
may provide insight regarding the relative contribution of such
materials to pharmaceutical degradation reactions.
Careful and thorough evaluation of pharmaceuticals exposed to
the space environment is overdue, and the paucity of data limits
appropriate translation of terrestrial studies for understanding of
space radiation exposures. It is critical to address these knowledge
gaps before missions to the moon or Mars are underway. There
are signiﬁcant advances that can be achieved by a well-planned
research effort that provides both actual ﬂight data from ﬂown
pharmaceuticals aboard available research platforms, such as the
ISS, as well as translational studies of comparative effects of spacelike radiation in terrestrial analogs, allowing for better interpretation of historical terrestrial radiation understanding in the context
of spaceﬂight. Use of improved and robust modeling techniques
that better simulate the space environment, careful study of
various formulations, alternate drug choices, and packaging
materials, and consideration of novel techniques, such as
cryogenic storage, could provide much-needed advances toward
the development of a pharmaceutical capability for interplanetary
ﬂight.
Reporting summary
Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
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